Novartis Hopes Eye Drug Beovu Bounces Back After New Approval
Gets EU Okay For Diabetic Macular Edema
Executive Summary
Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.